INmune Bio (INmune Bio) Float Percentage Of Total Shares Outstanding : 62.51% (As of Apr. 28, 2024)

View and export this data going back to 2019. Start your Free Trial

What is INmune Bio Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, INmune Bio's float shares is 11.73 Mil. INmune Bio's total shares outstanding is 18.77 Mil. INmune Bio's float percentage of total shares outstanding is 62.51%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, INmune Bio's Insider Ownership is 25.09%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, INmune Bio's Institutional Ownership is 7.00%.

INmune Bio Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

INmune Bio's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	11.73	/	18.77
	=	62.51%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

INmune Bio (INmune Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » INmune Bio Inc (NAS:INMB) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

225 NE Mizner Boulevard, Suite 640, Boca Raton, FL, USA, 33432

Website

https://www.inmunebio.com

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.

Executives

Scott Juda	director	325 N. LARCHMONT BLVD, SUITE 375, LOS ANGELES CA 90004
Timothy J Schroeder	director	2690 DEVILS BACKBONE ROAD, CINCINNATI OH 45233
David J Moss	10 percent owner, officer: CFO, Treasurer & Secretary	C/O PEGASI ENERGY RESOURCES CORPORATION, 218 N. BROADWAY, SUITE 204, TYLER TX 75702
Raymond Joseph Tesi	director, 10 percent owner, officer: President & CEO	476 MASSACHUSETTS AVE, UNIT 2, BOSTON MA 02118
Mark William Lowdell	10 percent owner, officer: Chief Scientific Officer	THE OAK, WLX ROAD, BEAUMONT X0 CO16 0AT
Linda F Powers	10 percent owner	7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
James Kelly Ganjei	director	10609 RIVER OAKS LANE, POTOMAC MD 20859
Marcia Allen	director	P.O. BOX 399, 2600 W. HOMESTEAD CIRCLE, WILSON WY 83014
Edgardo Jr Baracchini	director	C/O METABASIS THERAPEUTICS, 9390 TOWNE CENTRE DRIVE, BLDG. 300, SAN DIEGO CA 92121
Xencor Inc	10 percent owner	465 N. HALSTEAD ST., SUITE 200, PASADENA CA 91107
David Edmund Szymkowski	director	241 WEST PALM AVENUE, MONROVIA CA 91016